Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 37

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 37
---
 rate will be dramatically lower than what STAAR achieved in the 2020 to 2023 time period. While STAAR has innovative technology and management has been aggressively improving the cost profile of the business, STAAR is a single product company serving a narrow portion of an increasingly competitive market that has experienced demand challenges for several years in its largest market; STAAR needs a partner like Alcon to broaden its portfolio and better address its rapidly evolving risks. “If the Alcon merger does not move forward, we believe STAAR’s valuation will fall substantially, exposing stockholders to significant risk. The day prior to the announcement of the Alcon merger, STAAR’s stock closed at $18.49 per share following a more than 50% stock price decline in the prior year. STAAR’s consolidated Net Sales contraction that began in 2023 persisted into the first half of 2025, and procedure volumes continue to disappoint in China so far in the third quarter. “To ensure STAAR stockholders receive the compelling, certain, premium value of $28.00 per share in cash provided by the Alcon merger, we urge all STAAR stockholders to vote “FOR” the merger proposal on the WHITE proxy card TODAY.” Highlights of the presentation published todayinclude:

| • |     | The $28.00 per share all-cash consideration in the Alcon merger                                                                           
 agreement provides STAAR stockholders compelling, certain, cash value at a significant premium across multiple measures. It represents a: |

| • |     | 59% premium to STAAR’s 90-day volume weighted average price as of 
 the same date;                                                    |

| • |     | 47% premium to the median sell-side analyst price target of $19.00 per share as of just prior to the transaction 
 announcement; and                                                                                                |

| • |     | ~2.0x the median premium paid in comparable transactions. |

| • |     | STAAR faces sustained challenges as a standalone company. Although management has made progress mitigating                                                                                                                                        
 some near-term challenges, STAAR faces ongoing business headwinds that will continue to impact results – including overweight exposure to China, increasing competition, a limited product offering, historical inability to penetrate the market 
 beyond high myopia patients, and tariff risk.                                                                                                                                                                                                     |

| • |     | STAAR’s independent and experienced Board conducted a thoughtful evaluation of strategic                                                                                                                                                                  
 alternatives that considered standalone prospects, the industry landscape, and potential buyers. STAAR’s Board and management are actively involved in